Faculty introduction and disclosures

Introductory content  Epidemiology   Pathophysiology, clinical presentation, and recognition  aGvHD vs cGvHD

Treatment of cGvHD   Goals of therapy and prognosis  Overlap syndrome  Disease severity  Corticosteroid therapy and related treatment success vs. failure  Steroid-refractory disease: definitions and therapies  JAK inhibition  Rho-associated kinase inhibition  Calcineurin inhibition  Non-pharmacologic treatment approaches  Extracorporeal photopheresis  Psoralen ultraviolet radiation  Emerging therapies  Alpha-1 proteinase inhibition  α4β7-integrin inhibition  Additional agents targeting tyrosine kinase  Monitoring  Site-specific considerations  Clinical challenges: adherence, adverse effects, delays in therapy   Patient cases

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Review the epidemiology and pathophysiology of cGVHD.
• Describe the diagnostic and staging criteria in cGVHD.
• Discuss recent FDA-approved therapeutic agents for treatment refractory cGVHD.
• Formulate treatment plan for a patient with cGVHD.
• Describe the role of supportive care in cGVHD management.

ACCME Activity #202490640

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Catherine Lee, MD, Associate Professor of Medicine, Fred Hutch Cancer Center, has received financial compensation from Incyte, Kite pharma, BMS, Kadmo, CareDx, and Fresnius Kabi for consulting and/or research and/or speaker's bureau work.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will NOT discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Mallinckrodt.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version